Simultaneous Detection of Drug-Induced Liver Injury Protein and microRNA Biomarkers Using Dynamic Chemical Labelling on a Luminex MAGPIX System
Antonio Marín-Romero,
Mavys Tabraue-Chávez,
Bárbara López-Longarela,
Mario A. Fara,
Rosario M. Sánchez-Martín,
James W. Dear,
Hugh Ilyine,
Juan J. Díaz-Mochón,
Salvatore Pernagallo
Affiliations
Antonio Marín-Romero
DESTINA Genomica S.L. Parque Tecnológico Ciencias de la Salud (PTS), Avenida de la Innovación 1, Edificio BIC, Armilla, 18100 Granada, Spain
Mavys Tabraue-Chávez
DESTINA Genomica S.L. Parque Tecnológico Ciencias de la Salud (PTS), Avenida de la Innovación 1, Edificio BIC, Armilla, 18100 Granada, Spain
Bárbara López-Longarela
DESTINA Genomica S.L. Parque Tecnológico Ciencias de la Salud (PTS), Avenida de la Innovación 1, Edificio BIC, Armilla, 18100 Granada, Spain
Mario A. Fara
DESTINA Genomica S.L. Parque Tecnológico Ciencias de la Salud (PTS), Avenida de la Innovación 1, Edificio BIC, Armilla, 18100 Granada, Spain
Rosario M. Sánchez-Martín
GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, 18016 Granada, Spain
James W. Dear
Pharmacology, Therapeutics and Toxicology, Centre for Cardiovascular Science, The Queen’s Medical Research Institute, University of Edinburgh, 47 Little France Crescent, Edinburgh EH16 4TJ, UK
Hugh Ilyine
DESTINA Genomics Ltd., 7-11 Melville St., Edinburgh EH3 7PE, UK
Juan J. Díaz-Mochón
GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, 18016 Granada, Spain
Salvatore Pernagallo
DESTINA Genomica S.L. Parque Tecnológico Ciencias de la Salud (PTS), Avenida de la Innovación 1, Edificio BIC, Armilla, 18100 Granada, Spain
Drug-induced liver injury (DILI) is a potentially fatal adverse event and a leading cause for pre- and post-marketing drug withdrawal. Several multinational DILI initiatives have now recommended a panel of protein and microRNA (miRNA) biomarkers that can detect early liver injury and inform about mechanistic basis. This manuscript describes the development of seqCOMBO, a unique combo-multiplexed assay which combines the dynamic chemical labelling approach and an antibody-dependant method on the Luminex MAGPIX system. SeqCOMBO enables a versatile multiplexing platform to perform qualitative and quantitative analysis of proteins and miRNAs in patient serum samples simultaneously. To the best of our knowledge, this is the first method to profile protein and miRNA biomarkers to diagnose DILI in a single-step assay.
